Impactiviti Daily will not be published next week, as I will be attending the annual Society of Pharmaceutical and Biotech Trainers conference (SPBT) in Orlando.
As the pre-ASCO news heats up, the big headline will be leukemia treatments – specifically, BMS‘ Sprycel and Novartis‘ Gleevec and Tasigna (just in – Tasigna shown superior to Gleevec in slowing CML: 18-month results). Treatments in this class, by the way, are something near miracle drugs. They’ve totally revolutionized blood cancer treatments. In related news, Novartis’ Afinitor (approved for kidney cancer) meets goals in a trial for pancreatic cancer.
Why should you be interested in a “nanosponge”? Well, there’s this – Scientists have found that a delivery system based on a technique called nanosponge is three to five times more effective at reducing tumor growth than direct injection…more
Will Amgen‘s new osteoporosis drug Prolia find its true home in oncology treatment? - The company has also applied for FDA approval to market the drug to breast cancer and prostate cancer patients who are undergoing a hormone treatment that weakens their bones. What’s more, the company is conducting tests designed to show that Prolia prevents cancer from spreading to the bones — an indication that could push sales of the drug to as much as $6 billion annually, some analysts predict…more Also – huge sales force push for Prolia.
20% of high school students abuse prescription drugs. Wow – sobering.
Simulations/Gaming. Live training simulations, digital sims (eLearning) and on-line games – our partner network has the expertise you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
How to reduce e-mail ping-pong. You know all that back-and-forth? Here’s a way to undercut it at the start!
JUST FOR FUN
See-through animals. Ten of them. Amazing.
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board